CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
体内 CAR-T 工程化：2025 年 ASH 年会的洞见
英文原题：In vivo CAR-T engineering: insights from the 2025 ASH annual meeting.
查看英文原题
In vivo CAR-T engineering: insights from the 2025 ASH annual meeting.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
体内嵌合抗原受体（CAR）-T工程是癌症免疫学中一个重要的研究领域，其中载体被用于将内源性T细胞重编程为CAR-T 细胞。在第67届美国血液学会（ASH）年会上展示的病毒性和非病毒性平台提供了精准的T细胞靶向和高效的CAR表达。临床前模型证明了CAR-T 细胞的强劲生成、有效的肿瘤清除以及强大的临床转化潜力。然而，未来研究仍需解决某些局限性。本通信总结了会议的关键发现，讨论了当前的转化挑战，并强调了未来的方向。
展开英文摘要原文
In vivo chimeric antigen receptor (CAR)-T engineering is a prominent field of research in cancer immunology, in which vectors are used to reprogram endogenous T-cells into CAR-T cells. Viral and nonviral platforms presented at the 67th Annual Meeting of the American Society of Hematology (ASH) offer precise T-cell targeting and efficient CAR expression. Preclinical models demonstrated robust generation of CAR-T cells, potent tumor clearance, and strong clinical translational potential.
However, certain limitations remained to be addressed in future studies. This correspondence summarizes the key findings from the meeting, discusses current translational challenges, and highlights future directions.
论文信息
- 作者
- Asadi G、Rajabinejad M
- 第一作者单位
- Department of Immunology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran.Iran
- 通讯作者单位
- Department of Immunology, School of Medicine, Hamadan University of Medical Sciences, Hamadan, Iran. Misagh.ra@gmail.com.Iran
- 文献类型
- 读者来信
- 期刊
- Experimental hematology & oncology2026 Feb 26
- 原文标识
- PubMed 41749385 · DOI 10.1186/s40164-026-00762-8
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →